Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lintuzumab-Ac225 + CLAG-M in Relapsed/Refractory AML
NCT03441048Phase 1Completed
- Sponsor
- Medical College of Wisconsin
- Start
- May 2018
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of lintuzumab satetraxetan ac-225 in acute myeloid leukemia (AML) (6 arms), sponsored by Medical College of Wisconsin. Primary endpoints: Dose-Limiting Toxicities at 28 Days, Maximum-Tolerated Dose at 28 Days and 2 more. Started May 2018; status: completed.
02
Drugs
lintuzumab satetraxetan ac-225
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03441048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03441048.